Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for systemic use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis, to stimulate bowel motility after surgery, and to reverse the effects of non‑depolarizing neuromuscular blocking agents.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies globally, and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics.

Mestinon (pyridostigmine bromide) acts as an acetylcholinesterase inhibitor to enhance neuromuscular transmission in several clinical settings.

- Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. - Postoperative ileus: stimulates gastrointestinal motility to reduce postoperative bowel paralysis. - Reversal of non‑depolarizing neuromuscular blockade: counteracts residual blockade after anesthesia, facilitating recovery of muscle function.

Adverse reactions to pyridostigmine bromide vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring shortly after dosing. - Abdominal cramps: intermittent stomach discomfort. - Increased salivation: excess oral secretions. - Muscle cramps: involuntary tightening of skeletal muscles. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Bronchospasm: constriction of airway muscles, especially in asthmatic patients. - Severe bradycardia: markedly slow heart rate that may require medical attention. - Cholinergic crisis: excessive cholinergic activity leading to muscle weakness and respiratory compromise. - Seizures: rare central nervous system events. - Allergic reactions: rash, itching, or anaphylaxis in susceptible individuals.

When prescribing pyridostigmine bromide, clinicians should consider several safety measures.

- Monitor for cholinergic excess: watch for muscle twitching, sweating, bradycardia. - Adjust dose in renal impairment: reduced clearance may increase drug exposure. - Caution in asthma or COPD: risk of bronchospasm. - Avoid concurrent anticholinergic agents: may diminish therapeutic effect. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture.

Pyridostigmine bromide can interact with several medication classes.

Major Interactions (Avoid): - Beta‑blockers: may exacerbate bradycardia. - Succinylcholine: enhanced cholinergic effects leading to prolonged paralysis. - Other cholinesterase inhibitors: risk of cholinergic crisis.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): may reduce efficacy. - Diuretics that cause hypokalemia: can increase risk of muscle weakness.